Wednesday, September 07, 2022 Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma Morschhauser F, Nastoupil L, Feugier P, Schiano de Colella J-M, Tilly H, Palomba ML, Bachy E, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Le Gouill S, Daguindau N, Guidez S, Pica GM, García-Sancho AM, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Kalung W, Sehn LH, Izutsu K, Cartron G, Gkasiamis A, Crowe R, Xerri L, Fowler NH, Salles G. (ONLINE). J Clin Oncol JCO, 2022. https://ascopubs.org/doi/pdf/10.1200/JCO.22.00843 This is a second interim analysis of the RELEVANCE trial after 6 years of follow-up. The purpose of LY16 study was to find out if lenalidomide when given along with rituximab can help to control the disease and also increase the length of your response (complete or partial response) compared to the standard of care rituximab chemotherapy treatment. For more information please visit the LY16 CCTG trial page.
